CT引导下经皮微波消融治疗肾癌:2年随访的安全性与有效性
回顾性研究纳入62例患者共84个肾细胞癌肿瘤(直径10-48 mm,平均25.6 mm),在全身麻醉下接受CT引导经皮微波消融。24个月随访显示累积无病生存率95%、总生存率97%,并发症发生率4.8%,作者结论认为该技术安全且在24个月时提供高有效率。
要点
- CT引导经皮微波消融治疗肾细胞癌,24个月累积无病生存率95%、总生存率97%。
- 并发症发生率4.8%,包括1例III级和2例II级并发症(Clavien-Dindo分级)。
- 3个月时6个残余肿瘤(8%),6个月时2个复发和1个残余肿瘤(3.8%),均再次治疗成功。
核心结论
- CT引导下微波消融治疗肾细胞癌是安全的,并在24个月时提供高有效率。
研究设计与样本
- 回顾性研究,纳入62例患者共84个肾细胞癌肿瘤(直径10-48 mm,平均25.6 mm),肿瘤经组织学证实或影像学诊断为Bosniak IV级囊肿,在全身麻醉下接受CT引导经皮微波消融,随访24个月。
诊断标准与关键数值
- 技术成功78个肿瘤(58例患者);3个月时6个残余肿瘤(8%);6个月时2个复发和1个残余肿瘤(3.8%);12个月时94%病例达到局部疾病控制(所有接受治疗的病例为100%);2年累积无病生存率95%、总生存率97%。
临床应用与阅片要点
- 作者结论认为CT引导下微波消融治疗肾细胞癌安全且在24个月时提供高有效率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the safety and efficiency of percutaneous microwave ablation (MWA) of renal cell carcinomas (RCC) carried out under computed tomography (CT) guidance.
MATERIALS AND METHODS: A retrospective study was performed on RCC that was either histologically proven or diagnosed at imaging (Bosniak IV cyst) and treated by MWA under general anaesthesia with CT guidance. Indications for percutaneous ablation were based on the American Urological Association recommendations. Twenty-four months post-procedure follow-up was performed.
RESULTS: Sixty-two patients presenting one or more RCC (84 tumours ranging from 10-48 mm in diameter; mean diameter: 25.6 mm) were included. Technical success was achieved for 78 tumours (58 patients). For four patients, the treatment was stopped due to gas dissection failure. At 3 months, six residual tumours were observed (8%). At 6 months, two recurrences and one residual tumour (3.8%) were observed; all were retreated with complete success. At 12 months, local control of the disease was achieved in 94% of cases (100% in cases where treatment was performed). Two cases of distal metastasis were observed after 12 and 24 months. At 24 months, one patient presented with a contralateral tumour. The complication rate was 4.8% including one grade III complication and two grade II complications according to the Clavien-Dindo classification. At 2 years, the cumulative disease-free survival rate and overall survival were 95% and 97%, respectively.
CONCLUSION: MWA ablation under CT guidance to treat RCC is safe and provides a high rate of effectiveness at 24 months.
引用
- Chan P, Vélasco S, Vesselle G, et al. Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up. Clin Radiol. 2017. PMID: 28545682. doi:10.1016/j.crad.2017.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。